Iovance Biotherapeutics Inc
Change company Symbol lookup
Select an option...
IOVA Iovance Biotherapeutics Inc
EEX Emerald Holding Inc
JPM-L JPMorgan Chase & Co
SBFM Sunshine Biopharma Inc
SEKEY Seiko Epson Corp
PXMD PaxMedica Inc
CDT Conduit Pharmaceuticals Inc
FUSN Fusion Pharmaceuticals Inc
RDUS Schnitzer Steel Industries Inc
ALEC Alector Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company, which commercializes autologous T-cell therapy to address solid tumor cancer. It develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, lifileucel, is being developed in advanced, or metastatic or unresectable, melanoma, as well as in other indications. Lifileucel is investigated in two consecutive cohorts in a clinical trial of advanced melanoma patients post-anti-PD-1 therapy, including in a prospectively defined pivotal cohort. It has initiated Phase III clinical trial of lifileucel in combination with pembrolizumab, TILVANCE-301. The Company is also pursuing registrational strategies for lifileucel in advanced cervical cancer and for its TIL therapy, LN-145, in metastatic non-small cell lung cancer. Its first genetically modified, PD-1 inactivated TIL therapy, IOV-4001, is under Phase I/II clinical trial, IOV-GM1-201.

Postmarket

Last Trade
Delayed
$4.59
0.0189 (0.41%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$4.57
Day's Change
-0.30 (-6.16%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
4.84
Day's Low
4.51
Volume
(Light)
Volume:
10,783,052

10-day average volume:
17,941,113
10,783,052
  • Prev Close
    4.87
  • Today's Open
    4.83
  • Day's Range
    4.51-4.84
  • Avg Vol (10-day)
    17.9M
  • Last (time)
    4:00p ET 09/25/23
  • Last (size)
    650
  • 52-Wk Range
    4.41 - 10.41
    LowHigh
  • (10/07/22 - 09/14/23)
    3.63%
  • 77.4%
  • Market Cap
    1.1B
  • Shares Outstanding
    247.8M
  • -2.25
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 0.1
  • 89.02
  • (% of float 08/31/23)
    12.91

Latest News

September 22, 2023
6:25 pm ET
Globe Newswire
September 18, 2023
9:31 am ET
PR Newswire
September 15, 2023
1:40 pm ET
MarketWatch
9:31 am ET
PR Newswire
6:26 am ET
Zacks
September 14, 2023
6:10 pm ET
Globe Newswire
September 07, 2023
10:30 am ET
Zacks
7:31 am ET
Globe Newswire
August 18, 2023
5:00 pm ET
Globe Newswire
August 09, 2023
10:14 am ET
Zacks
August 08, 2023
4:50 pm ET
Zacks
4:01 pm ET
Globe Newswire
July 25, 2023
4:01 pm ET
Globe Newswire
July 24, 2023
4:01 pm ET
Globe Newswire
July 21, 2023
5:34 pm ET
Globe Newswire
July 13, 2023
4:01 pm ET
Globe Newswire
July 10, 2023
9:46 pm ET
Globe Newswire
4:34 pm ET
Globe Newswire
7:00 am ET
Globe Newswire
May 30, 2023
3:02 pm ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.